Australian Particle Therapy Clinical Quality Registry


Australian Particle Therapy Clinical Quality Registry (ASPIRE) is a prospective, observational, longitudinal study of paediatric, adolescent, young adult and rare adult tumour patients from a select group of tumour streams treated with radiation therapy. Comparing the long-term toxicities of photon and proton radiation therapy.

For more about ASPIRE visit: https://www.protontherapy.sahmri.org.au/about-aptcqr/

Primary Sponsor

South Australian Health & Medical Research Institute (Australian Bragg Centre for Proton Therapy and Research)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Trial Chairperson

A/Prof Hien Le, Royal Adelaide Hospital, SA, Australia

Trial Contact

ASPIRE@sahmri.com

Clinical Trial Registration

Related Post

17 November, 2026

Every kilometre counts: TROG supporters go the distance for cancer research

LATEST NEWS: 17 November 2026 From early morning walks

10 November, 2026

Golfers tee off for annual TROG fundraiser

LATEST NEWS: 10 November 2026 The Myall Coast Veteran